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Abstract
The effective magnetic resonance imaging (MRI) trans-
verse relaxation rate R2* was investigated as an early
acute marker of the response of rat GH3 prolactinomas
to the vascular-targeting agent, ZD6126. Multigradient
echo (MGRE) MRI was used to quantify R2*, which is
sensitive to tissue deoxyhemoglobin levels. Tumor R2*
was measured prior to, and either immediately for up
to 35 minutes, or 24 hours following administration of
50 mg/kg ZD6126. Following MRI, tumor perfusion was
assessed by Hoechst 33342 uptake. Tumor R2* sig-
nificantly increased to 116 ± 4% of baseline 35 minutes
after challenge, consistent with an ischemic insult in-
duced by vascular collapse. A strong positive corre-
lation between baseline R2* and the subsequent
increase in R2* measured 35 minutes after treatment
was obtained, suggesting that the baseline R2* is
prognostic for the subsequent tumor response to
ZD6126. In contrast, a significant decrease in tumor
R2* was found 24 hours after administration of ZD6126.
Both the 35-minute and 24-hour R2* responses to
ZD6126 were associated with a decrease in Hoechst
33342 uptake. Interpretation of the R2* response is
complex, yet changes in tumor R2* may provide a
convenient and early MRI biomarker for detecting the
antitumor activity of vascular-targeting agents.
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Introduction
It is now well-established that the development, growth, and
survival of solid tumors are highly dependent on a functional
vascular network [1]. Established blood vessels, which
consist of endothelial cells, support cells, and a basement
membrane, provide tumor cells with oxygen and nutrients,
and enable the removal of toxic waste products of cellular
metabolism. Physiological angiogenesis is a tightly regu-
lated process that occurs only in a limited number of
situations such as wound healing or during the menstrual cycle.
In contrast, in several pathologic situations, including cancer,
angiogenesis is dysregulated [2]. As a result, tumor vascula-
ture has a very different morphology compared with normal
tissues. For example, in a normal adult, most of the vascular
endothelium is quiescent, with only 0.01% of endothelial cells
undergoing division, whereas in tumors, the expression of
proangiogenic growth factors can result in an endothelial cell
proliferation rate 35-fold higher than that of normal tissues [3,4].
Differences between normal and tumor endothelium are now
being exploited with novel therapies to selectively target the
proliferating tumor endothelium while leaving the normal
blood vessels relatively unaffected [5]. This strategy has sev-
eral advantages. In particular, the dependence of tumor
cells on functional blood vessels means that damage to rela-
tively few endothelial cells could result in the death of many
tumor cells [2,6–8].
ZD6126 (N-acetylcolchinol-O-phosphate) is a vascular-
targeting agent shown to have significant antitumor effects,
both against a wide range of rodent and human tumor model
systems [9–17] and against human tumor vasculature in the
clinic [15]. ZD6126 is rapidly converted by serum phospha-
tases to N-acetylcolchinol (NAC), and studies in vitro have
shown that NAC disrupts the tubulin cytoskeleton and induces
rapid changes in the endothelial cell morphology of proliferat-
ing, but not confluent, endothelial cells [18]. In vivo, disruption
of the tumor endothelium has been shown within an hour of
ZD6126 administration [11], with these early changes followed
by thrombosis and vessel occlusion resulting in massive
central tumor necrosis 24 hours after treatment. A common
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histologic observation is the existence of a viable rim of
tumor cells that survives treatment with ZD6126. Vascular-
targeting agents alone typically result in tumor growth delay,
but not regression—presumably a consequence of continued
growth from this surviving viable rim [10–12].
Methods for the assessment of tumor vasculature are
continually being sought to provide quantitative sensitive
indices of tumor pathophysiology and response that can be
translated to the clinic [19,20]. As many vascular-targeting
agents are not expected to induce rapid tumor regressions
as single-agent therapies, their clinical development will
benefit greatly from the use of biomarkers. In particular,
magnetic resonance imaging (MRI) provides a number of
potential imaging biomarkers associated with tumor blood
vasculature and its response to therapy, which require
evaluation before they can be deployed in clinical trials.
Dynamic contrast-enhanced (DCE) MRI has been used to
demonstrate the dose-dependent activity of ZD6126 in two
rodent tumor models, rat GH3 prolactinomas [14] and
murine colon 38 carcinomas [15]. In particular, the effect
of 50 mg/kg ZD6126 on rat GH3 prolactinomas was pro-
found 24 hours after administration. However, DCE MRI is
unsuited to hyperacute measurements because several
hours must elapse between measurements to permit con-
trast agent elimination.
We are currently further investigating the use of intrinsic
susceptibility MRI, which utilizes endogenous deoxyhemo-
globin as the primary source of image contrast, to assess
tumor response to ZD6126. Deoxyhemoglobin is paramag-
netic and its presence creates magnetic susceptibility pertur-
bations around blood vessels, thus increasing the effective
transverse magnetic resonance relaxation rateR2* of the sur-
rounding tissue in proportion to the tissue deoxyhemoglobin
concentration. In the absence of other changes, R2* depends
on tissue deoxyhemoglobin levels and hence may provide an
acute index of changes in tissue oxygenation. We originally
hypothesized that following treatment with ZD6126, hemo-
globin within erythrocytes would deoxygenate, resulting in an
increase in tumor R2*. Intriguingly, in a pilot study designed
to establish efficacy of ZD6126 on rat GH3 prolactinomas,
tumor R2* was found to decrease 24 hours after treatment,
and this correlated with massive hemorrhagic necrosis [14].
The aims of the present study were to investigate the use of
tumor R2* as an early acute marker of tumor response to
ZD6126 and provide appropriate histologic validation of any
MRI findings.
Materials and methods
Animals, Tumors, and Study Protocol
All experiments were performed in accordance with the
local ethical review panel, the UKCCCR guidelines [21], and
the UK Home Office Animals Scientific Procedures Act 1986.
Rat GH3 prolactinomas were grown in the flanks of 27 female
Wistar Furth rats [22]. Anesthesia was induced with a 4 ml/kg
intraperitoneal injection of fentanyl citrate (0.315 mg/ml) plus
fluanisone (10mg/ml) (‘‘Hypnorm’’; Janssen Pharmaceutical,
Ltd.), midazolam (5 mg/ml) (‘‘Hypnovel’’; Roche), and water
(1:1:2). Tumor volume was measured using calipers, assum-
ing an ellipsoidal shape. The mean tumor volume at the time
of randomization to treatment groups was 2.43 ± 0.2 cm3.
Two MRI study protocols were performed. The first was
designed to monitor tumor R2* immediately following admin-
istration of ZD6126, whereas the second was designed to
measure tumor R2* and R2 prior to and 24 hours following
treatment with ZD6126.
Intrinsic Susceptibility Contrast MRI—Study 1
MRI was performed on a Varian Unity Inova system
interfaced to a 4.7-T horizontal magnet, using a three-turn,
25-mm–diameter imaging coil. A lateral tail vein was cannu-
lated with a 27-G butterfly needle for administration of either
ZD6126 or saline. The rats were positioned so that the tumor
hung vertically into the imaging coil and covered with a warm
water blanket to maintain the core temperature at 37jC. Field
homogeneity was optimized by shimming on the water signal
for each tumor to a linewidth of ca. 50 Hz.
Multigradient echo (MGRE) images were acquired using
a train of eight echoes spaced 5 milliseconds apart, an initial
echo time of 5 milliseconds, with a flip angle a = 45j and a
repetition time of 80 milliseconds. Images were acquired
from five contiguous 1-mm–thick transverse slices through
each tumor, using four averages of 256 phase encode
steps over a 4  4 cm field of view (FOV), giving a temporal
resolution of 7 minutes. Two baseline MRI data sets were
acquired to enable an assessment of the repeatability of the
R2* measurement, followed by a further five data sets (at
7, 14, 21, 28, and 35 minutes) after administration of either
saline, 30 or 50 mg/kg ZD6126, i.v.
Immediately after the final MRI acquisition, the rats were
rapidly removed from the magnet bore and injected with
15 mg/kg of the perfusion marker Hoechst 33342 through
the tail vein. Hoechst 33342 is a dye that stains the nuclei
of endothelial cells, lining blood vessels that are perfused at
the time of injection, and thus affords a measure of functional
tumor vasculature. One minute later, the rats were sacrificed
by cervical dislocation and the tumors rapidly excised and
frozen over liquid nitrogen.
Intrinsic Susceptibility Contrast MRI—Study 2
In this study, MGRE MRI was performed on GH3 prolacti-
nomas prior to treatment as described above, except that
images were acquired from a single 1-mm–thick transverse
slice through the center of each tumor, using eight averages
of 256 phase encode steps over a 4 4 cm FOV. In addition,
spin echo images with TE = 11, 20, 30, and 40 milliseconds,
and TR = 300 milliseconds were acquired from the same
central slice andFOV. The total imaging timewas 14minutes.
The rats were then treated intravenously with either saline or
50 mg/kg ZD6126 and the tumors subsequently imaged
again 24 hours later, with the tumor being positioned carefully
within the coil so as to afford a degree of registration of the
MR images with those acquired prior to treatment. Following
MRI, the rats were administered 15 mg/kg Hoechst 33342
and the tumors excised as above.
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MRI Data Analysis
Tumor R2* and R2 maps for each slice were calculated
from the image data sets by fitting a single exponential to the
signal intensity echo time curve pixel-by-pixel [23,24]. The
mean R2* and R2 for each slice from each individual tumor
were determined from a region of interest (ROI) encompass-
ing the whole tumor but excluding the surrounding skin/
muscle. In addition, for study 2, maps of R2V (= R2*  R2)
were synthesized and the mean R2V determined. Frequency
histograms for each slice were also derived from the ROI to
assess the distribution of R2* values.
Fluorescence Microscopy
Contiguous frozen sections through each tumor (10 mm)
were subsequently cut on a cryotome in approximately
the same plane as for the MRI, and stored at 80jC until
processed. Sections were fixed in ice-cold acetone for
10 minutes and then mounted in phosphate-buffered saline.
Hoechst 33342 fluorescence signals from whole tumor sec-
tions were then recorded at 365 nm using a motorized
scanning stage (Prior Scientific Instruments Ltd., Cam-
bridge, UK) attached to a BX51 microscope (Olympus Opti-
cal Co. Ltd, London, UK), driven by analysis (Soft Imaging
System, Munster, Germany). Digital images from all the
tumors were acquired using the same exposure time and
composite images were then synthesized [25]. Fluorescent
particles were detected above a constant threshold for all
the composite images and the area of the tumor section with
Hoechst 33342 fluorescence determined and expressed
as a percentage of the whole tumor section (mean Hoechst
Figure 1. Tumor R2* maps and associated frequency histograms obtained from one transverse slice through a rat GH3 prolactinoma (a) prior to, (b) 7 minutes,
(c) 21 minutes, and (d) 35 minutes following administration of ZD6126, 50 mg/kg, i.v. The frequency histograms were acquired from an ROI that encompassed
the whole tumor but excluded the surrounding skin/muscle. Note the skewing of the distribution of R2* pixel values toward faster values following administration
of ZD6126.
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perfused area, or mHPA). As the images were acquired and
analyzed under identical conditions, any differences in
mHPAwould result from differences in tumor perfusion. Thus
these data could be used to validate any changes in intrinsic
R2* contrast induced by ZD6126.
Statistical Analysis
Results are presented in the form mean ± SEM. Unless
otherwise stated, significance testing employed the two-
tailed t-test, assuming unequal variances with a 5% level of
significance. Repeatability of the R2* measurement was
assessed using a Bland-Altman plot for differences and
confidence intervals, and also by derivation of the intra-
tumoral coefficient of variation [26].
Results
Serial R2* maps and associated frequency histograms from
one GH3 prolactinoma from study 1, treated with 50 mg/kg
ZD6126, are shown in Figure 1. For all the tumors studied,
the baseline R2* maps were typically heterogeneous and
exhibited a symmetrical distribution of R2* values. The intra-
tumoral coefficient of variance (rms CoV) for the baselineR2*
measurements within each tumor was 1.7%. Using all the
successive baseline R2* measurements in study 1 before
treatment, the repeatability of the R2* measurement was
determined. From the Bland-Altman analysis, the 95% con-
fidence interval between the two pretreatment R2* measure-
ments was [9.5 sec1, 8 sec1]. This confidence interval
contains 0 (i.e., we would fail to reject the null hypothesis
that d = 0, where d is the difference between the two
pretreatment R2* measurements) and is extremely small
compared to the range of R2* values (83–135 second
1).
Application of a paired two-sample t-test showed that there
was no significant difference between the means of the
two baseline R2* measurements (P = .52). Taken together,
these findings clearly show an excellent repeatability of the
R2* measurement.
Administration of saline induced no significant change in
the R2* maps and distribution (data not shown), whereas
administration of ZD6126 induced a marked increase in R2*
over the first 35 minutes of challenge. Localized increases in
R2* could be discerned qualitatively as early as 7 minutes
after administration of ZD6126, with statistically significant
increases found 14 minutes post 50 mg/kg ZD6126
(P < .02). Visual inspection of the R2* maps showed that
tumor regions exhibiting a relatively fast (intense) basal R2*
showed the greatest increase in R2* over 35 minutes in
response to ZD6126 (Figure 1). The time course of R2*
response for all the tumors in study 1 is shown in Figure 2,
which shows that whereas all six saline-treated tumors
showed little change in R2*, 9 of 10 tumors treated with
ZD6126 showed an increase in R2*. To identify any trends
within a treatment group, a Jonckheere-Terpstra test was
applied to the data. This is a nonparametric test for ordered
differences in R2* among classes (e.g., dose, time), which
tests the null hypothesis that the distribution of R2* does not
differ among the classes and thus essentially tests for a
monotonic response. No significant trend in response (cor-
rected for baseline values) was observed for the saline-
treated group (P = .28), whereas for both the 30- and
50-mg/kg treatment groups, a significant monotonic re-
sponse was observed up to 35 minutes with P values of
P = .0023 and P = .0051, respectively.
Composite fluorescence images of Hoechst 33342 tumor
uptake are shown in Figure 3, in which a decrease in tumor
perfusion with ZD6126 treatment can be seen. A summary of
the data acquired from study 1 is shown in Table 1.
The R2* maps and frequency histograms shown in
Figure 4 were acquired from one GH3 prolactinoma prior
to and 24 hours following treatment with 50 mg/kg ZD6126,
as part of study 2. Control tumors maintained a relatively
Figure 2. Profile plots of R2* (mean R2* of all five transverse slices) for each individual rat in study 1. Two baseline MGRE MRI data sets to quantify R2* were
acquired prior to intravenous administration of (a) saline (n = 6), (b) 30 mg/kg ZD6126 (n = 3), or (c) 50 mg/kg ZD6126 (n = 7), after which a further five MGRE MRI
data sets were acquired. A statistically significant increase in R2* was found 14 minutes after administration of 50 mg/kg ZD6126 (paired two-sample t-test, P < .02).
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constant and heterogeneous distribution of R2* values
24 hours after administration of saline (data not shown). In
contrast, treatment with ZD6126 resulted in both a decrease
and a more homogeneous distribution of R2* values over the
whole tumor (Figure 4). The individual R2* values pre- and
24 hours posttreatment for all the tumors in study 2 are
shown in Figure 5. All five tumors treated with saline showed
a small, nonsignificantR2* increase 24 hours after challenge,
whereas all six tumors treated with ZD6126 showed a strik-
ing reduction in R2*. A similar response was also found for
both tumorR2 andR2V. As in study 1, composite fluorescence
images of Hoechst 33342 tumor uptake revealed a dra-
matic reduction in the perfusion of ZD6126-treated tumors
(Figure 6). The data from study 2 are summarized in Table 2.
The data shown in Figure 2c suggest that tumors exhibit-
ing a relatively fast basal R2* subsequently showed the
greatest increase in R2* 35 minutes after treatment with
50 mg/kg ZD6126. By simply plotting the average baseline
R2* against the change in R2* at 35 minutes, a correlation
would be expected even when there may be no relationship
[26]. To overcome this and to test whether the baseline tumor
R2* was predictive for the subsequent magnitude of re-
sponse to ZD6126, the average of the final and mean
baseline R2* was plotted against the change in R2* mea-
sured 35 minutes after challenge for each tumor (Figure 7).
A significant and strong positive correlation was obtained
(r = 0.899, P < .01), which was greater than the correlation
of 0.7 we would expect to see by chance [26]. No such cor-
relation was obtained for the tumors imaged 24 hours after
treatment with ZD6126 (r = 0.331, P > 0.1).
Discussion
Noninvasive imaging techniques are continually being de-
veloped for the assessment of tumor vascular function and
its therapeutic response. As the oxygenation of hemoglobin
is proportional to arterial blood paO2 and therefore in equi-
librium with tissue pO2, quantitation of the relaxation rate R2*
by MGRE MRI provides a sensitive index that, under some
circumstances, may relate to tissue oxygenation. Further-
more, the method is completely noninvasive, relying inter alia
on intrinsic deoxyhemoglobin for image contrast rather than
an exogenously administered contrast agent.
The presence of paramagnetic deoxyhemoglobin in blood
vessels produces an additional relaxation rate term in the
surrounding tissue that is linearly dependent on the blood
volume fraction and the magnetic susceptibility difference
between the surrounding tissue and in the blood vessels [27].
The total R2* relaxation rate of tissue can be written as:
R2 ¼ R2 þ R V2þ kibviHcti ð1 Yi ÞDv ð1Þ
where R2 and R2V represent the irreversible and reversible
relaxation rates, respectively, in tumor tissue in the absence
Figure 3. Composite fluorescence images of Hoechst 33342 uptake into rat GH3 prolactinomas ca. 35 minutes after administration of either (a) saline or (b)
50 mg/kg ZD6126. The composite image shown in (b) is taken from the same tumor shown in Figure 1.
Table 1. Summary of the Data Acquired from Study 1.
Pretreatment 35 min Postsaline Pretreatment 35 min Post 30 mg/kg ZD6126 Pretreatment 35 min Post 50 mg/kg ZD6126
R2* (sec
1) 110 ± 6 108.7 ± 6 90.8 ± 4 114.4 ± 7 106.4 ± 6 123.2 ± 10y
mHPA (%) 13.6 ± 2 4.8 ± 1* 9.1 ± 1
Tumor R2* was measured prior to and immediately following administration of either saline (n = 6), 30 mg/kg ZD6126 (n = 3), or 50 mg/kg ZD6126 (n = 7), i.v., for up
to 35 minutes.
Tumor perfusion was assessed by Hoechst 33342 uptake (mHPA).
Treatment with ZD6126 resulted in an increase in tumor R2* over 35 minutes of challenge and was consistent with a decrease in tumor perfusion.
Values are mean ± 1 SEM.
*P < .05.
yP < .01.
*
470 Acute Tumor Response to ZD6126 Assessed by MRI Robinson et al.
Neoplasia . Vol. 7, No. 5, 2005
of deoxyhemoglobin, and the last term represents the re-
laxation in the tumor tissue due to the presence of deoxy-
hemoglobin. Hct is the hematocrit, Y is the fraction of
oxygenated blood, bv is the fraction of tissue occupied by
blood vessels, Dv is the absolute susceptibility difference
between fully oxygenated and deoxygenated blood, and k is
a term dependent on blood vessel morphology and magnetic
field strength. The subscript i indicates that there should be a
summation over arterial, capillary, and venular vascular net-
works [28]. We can use Eq. (1) throughout the discussion to
help interpret how the observed changes in tumor R2*
following administration of ZD6126 relate to the underlying
physical processes.
Study 1
Our underlying hypothesis was that following treatment
with ZD6126, hemoglobin within erythrocytes would deoxy-
genate, resulting in an increase in tumor R2*. Tumor R2*
increased over the first 35 minutes of challenge with either
30 or 50 mg/kg ZD6126 and was associated with a decrease
in tumor perfusion as indicated by the reduced uptake of
Hoechst 33342. This early R2* response is consistent with
the induction of an ischemic insult induced by vascular
shutdown/collapse, in agreement with our original hypo-
thesis. An increase in tumor R2* could be observed as early
as 7 minutes after administration of ZD6126. Increases in
tumor R2* were also seen with the more clinically relevant
dose of 30 mg/kg ZD6126. A similarly acute response to the
vascular-targeting agent combretastatin A-4 phosphate has
been shown by intravital microscopy of rat P22 carcino-
sarcomas grown in window chambers [29]. A hyperacute
increase in tumor R2* in response to photodynamic therapy
has also been recently reported [30].
The hyperacute increase inR2* following administration of
ZD6126 is most likely due to tumor blood becoming more
deoxygenated (a decrease in Y ) as a consequence of
reduced tumor blood flow due to the onset of vascular
collapse or thrombosis. According to the Poiseuille equation
for viscous laminar flow through a vessel, if blood pressure is
maintained constant, a 10% reduction in vessel radius (which
is a 20% reduction in vascular volume) will produce a 40%
reduction in blood flow. Thus, although according to Eq. (1) a
reduction in bv may be expected to decrease R2*, it is not
unreasonable to expect changes in Y to initially predominate.
Also, if the erythrocytes are trapped within the blood vessels
so that it is just a reduction in plasma that occurs and not a
reduction in erythrocyte density, then the product Hctbv
remains constant and changes in R2* are again dominated
by the reduction in Y. Alternatively, occlusion of just a few
arteriolar supply vessels could cause widespread reduction
of blood flow in the capillary bed and hence a large decrease
in Y.
Analysis of the R2* maps from study 1 showed that those
voxels exhibiting a relatively fast basal R2* subsequently
Figure 4. Tumor R2* maps acquired from one rat GH3 prolactinoma (a) prior
to and (b) 24 hours posttreatment with ZD6126, 50 mg/kg, i.v. The associated
frequency histograms for these maps are shown in (c). Note the dramatic
decrease in both the distribution and pixel values of R2* 24 hours after
treatment with ZD6126.
Figure 5. Line series of R2* for each individual rat in study 2. Tumor R2* was measured from a single transverse slice prior to and 24 hours after intravenous
administration of either (a) saline (n = 5) or (b) 50 mg/kg ZD6126 (n = 6).
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showed the greatest initial increase in R2* in response to
ZD6126. Furthermore, a strong positive correlation between
the baseline tumor R2* and the subsequent hyperacute
increase in R2* measured 35 minutes after treatment with
50 mg/kg ZD6126 was obtained (Figure 7). This suggests
that the baseline R2* has: 1) prognostic value for subsequent
tumor response to ZD6126, and 2) is a predictor of the
magnitude of the acute R2* increase following treatment.
We have previously shown that intense regions (relatively
fast R2*) in the baseline R2* maps of GH3 prolactinomas are
consistent with the presence of perfused vascularized tissue
with relatively high deoxyhemoglobin concentrations (i.e.,
large blood volume), whereas dark regions (relatively slow
R2*) may indicate more poorly vascularized tissue in which
the capillaries have a limited ability to transport erythrocytes
[31]. Furthermore, we have demonstrated that the relatively
fast tumor R2* measured in rat GH3 prolactinomas is prog-
nostic for an acute radiotherapeutic response [32]. Thus, the
early R2* response to ZD6126 most likely reflects well-
perfused tumor regions to which the vascular-targeting agent
is rapidly delivered. It could also be speculated that these
same tumor regions are also under hypoxic stress, which
induces neovascularization, but we have no direct hypoxia
measurement (e.g., pimonidazole adduct formation) for the
tumors in this study. Nevertheless, we have recently shown
that mutant C6 gliomas with a relatively fast basal R2* and
larger blood volume compared to wild type were also more
hypoxic [33], whereas a preliminary clinical study has shown
that human prostate tumors exhibiting a relatively fast R2*
stained positive for pimonidazole whereas those tumors with
slow R2* stained negative [34].
Study 2
A small nonsignificant increase in tumor R2* was found
24 hours after treatment with saline, consistent with an in-
crease in deoxyhemoglobin as the tumor grows. In contrast
to our hypothesis, tumorR2* significantly decreased 24 hours
posttreatment with 50 mg/kg ZD6126, but which also cor-
related with a significant decrease in tumor perfusion mea-
sured by Hoechst 33342 uptake. The magnitude of the
decrease in R2* of GH3 prolactinomas following treatment
is similar to our previous observations and associated with
massive central necrosis at this time point [14]. The disrup-
tion of the tumor blood vessel cytoskeleton by ZD6126
causes complete vessel collapse and stacking of the fully
deoxygenated erythrocytes into rouleaux. The erythrocytes
would now be expected to be fully deoxygenated so that
Y = 0 in Eq. (1) and hence any changes in R2* must relate
to changes in the other parameters. If some tumor blood
flow remains, it is possible that there is a reduction in Hct
as the vessels collapse, and as Hct decreases with vessel
size [35], R2* would decrease.
From Eq. (1), there are several possibilities that would
allow R2* to decrease. For example, either the number of
erythrocytes per unit volume of tumor tissue is not constant
and decreases, or R2 + R2V decreases. The first case could
be true if erythrocytes are being cleared by macrophages,
but this seems unlikely 24 hours after treatment with
ZD6126. Another explanation is that there is an increase
in the water/macromolecule ratio due to the presence of
edema, which would cause a decrease inR2. Accordingly, we
found a significant decrease in tumor R2 measured 24 hours
Figure 6. Composite fluorescence images of Hoechst 33342 uptake into rat GH3 prolactinomas 24 hours after administration of either (a) saline or (b) 50 mg/kg
ZD6126. The composite image shown in (b) is taken from the same tumor shown in Figure 4.
Table 2. Summary of the Data Acquired in Study 2.
Pretreatment 24 hr
Postsaline
Pretreatment 24 hr Post 50
mg/kg ZD6126
R2* (sec
1) 109.2 ± 14 123.6 ± 17 114.6 ± 10 63 ± 8y
R2 (sec
1) 45.3 ± 3 46.3 ± 3 44.7 ± 3 34.9 ± 2*
R2V (sec1) 67 ± 11 75.7 ± 13 68.7 ± 7 23.9 ± 7y
mHPA (%) 17.4 ± 3 5.3 ± 1y
Tumor R2* and R2 were measured prior to and 24 hours after administration
of either saline (n = 5) or 50 mg/kg ZD6126 (n = 6), i.v.
Tumor R2V was determined from synthesized difference maps (R2*  R2).
Tumor perfusion was assessed by Hoechst 33342 uptake (mHPA).
A significant decrease in R2*, R2, and R2V was measured 24 hours after
treatment with ZD6126, associated with a significant decrease in tumor
perfusion.
Values are mean ± 1 SEM.
*P < .02.
yP < .001.
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after 50 mg/kg ZD6126. However, this response constituted
only ca. 20% of the decrease in tumor R2*. Synthesis of R2V
maps (= R2*  R2), which are highly sensitive to magnetic
field inhomogeneities [36], revealed that the decrease
in tumor R2* was clearly dominated by a decrease in R2V
(Table 1). The striking reduction in R2V clearly indicates the
absence of any paramagnetic deposits at this time point and
is associated with massive central necrosis in GH3 prolac-
tinomas as previously reported [14,16]. The pathophysio-
logical processes responsible for the decrease in tumor R2V
following treatment with ZD6126 are unclear, but may be
a consequence of the denaturation of paramagnetic deoxy-
hemoglobin by methemoglobin to diamagnetic hemi-
chromes, shown to cause a decrease in the transverse
relaxation rate of chronic brain hemorrhage [37,38].
Conclusion
Measurement of tumor R2* could be included in clinical trial
protocols of vascular-targeting agents in which DCE MRI is
already being used to assess drug activity [15]. The MGRE
MRI method is available on most clinical scanners and
measurements of human tumor R2* have been reported
[34,39]. Recent preliminary clinical data have shown similar
time-dependent oscillations in human tumor R2* following
treatment with the vascular-targeting agent combretastatin
A4 phosphate [40]. Clearly, the interpretation of R2* changes
is complex because, as we have shown, both increases and
decreases in R2* can occur at efficacious doses of vascular-
targeting agents. Nevertheless, a change in tumor R2* may
provide a convenient and early MRI biomarker for detecting
acute changes induced by vascular-targeting agents.
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